GC012F injection for hard-to-treat myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests an investigational drug called GC012F for people with generalized myasthenia gravis (gMG) that hasn't improved with standard treatments. The goal is to see if it can reduce symptoms and improve daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of generalized myasthenia gravis (gMG) that is moderate to severe (classes IIa to IVb).
- Your symptoms must be significant, with a score of at least 6 on the MG-ADL scale (which measures how myasthenia gravis affects daily activities) and at least 11 on the QMG scale (which measures muscle strength).
- You must have tried standard treatments (like steroids, immune-suppressing drugs, or rituximab) and they haven't worked well enough or you've had a bad reaction.
- If you are on steroids (prednisone), your dose must be 30 mg per day or less and stable for at least 4 weeks before starting the study.
- You must be willing to use effective birth control and not become pregnant or father a child for at least 2 years after getting the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests a new cell therapy (GC012F) for people with difficult-to-treat generalized myasthenia gravis. The treatment aims to reset the immune system to reduce muscle weakness.
This trial tests an experimental drug (EA5) injected under the skin or into a vein for people with a specific form of myasthenia gravis (caused by AChR antibodies). The goal is to find the safest dose and see how well it may reduce muscle weakness.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial tests a new cell therapy called CABA-201 for people with generalized myasthenia gravis. It aims to reset the immune system to reduce muscle weakness and improve daily functioning.
This trial tests a new cell therapy (GC012F) for people with idiopathic inflammatory myopathy (IIM) that hasn't responded to standard treatments. It aims to see if this treatment can help control muscle inflammation and weakness.
This trial tests an investigational drug called SHR-2173, given as an injection, for people with generalized myasthenia gravis. It aims to see if the drug can improve muscle strength and daily function.
Hear when a new Generalized Myasthenia Gravis (gMG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.